Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Axalimogene filolisbac (Primary) ; Durvalumab (Primary)
- Indications Cervical cancer; Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Advaxis
- 13 Jun 2017 According to an Advaxis media release, case study data from this trial presented at annual Investor & Analyst Day.
- 09 Jan 2017 According to an Advaxis media release, updated data from this trial are expected in the second half of 2017.
- 26 Sep 2016 According to an Advaxis media release, this trial will be poster presented at the Society for Immunotherapy of Cancer's (SITC) 31st Annual Meeting and Associated Programs, 2016.